Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTACC: Heparin Anticoagulation for COVID-19
NCT04372589Phase 3Completed
- Sponsor
- University of Manitoba
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of heparin in coronavirus disease 2019 (COVID-19), sponsored by University of Manitoba. Started May 2020; status: completed.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04372589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372589.